# Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

> **NCT00200343** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 596 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ursodeoxycholic acid 150mg / day
- **DRUG:** Ursodeoxycholic acid 600mg / day
- **DRUG:** Ursodeoxycholic acid 900mg / day

## Key facts

- **NCT ID:** NCT00200343
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00200343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00200343, "Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT00200343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*